六氯环己烷
CD8型
肝细胞癌
肿瘤微环境
病理
医学
免疫系统
流式细胞术
癌症研究
免疫学
作者
Stefan M. Brunner,Christoph Rubner,Rebecca Kesselring,Maria Martin,Eva Griesshammer,Petra Ruemmele,Thomas Stempfl,Andreas Teufel,Hans J. Schlitt,Stefan Fichtner‐Feigl
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2015-01-31
卷期号:61 (6): 1957-1967
被引量:93
摘要
Interleukin‐33 (IL‐33), a cytokine with pleiotropic functions, is elevated in serum of patients with hepatocellular carcinoma (HCC). This study investigated the effects of local IL‐33 expression in resected HCC on patient survival and on the immunological and molecular tumor microenvironment. Tissue of resected HCCs was stained for hematoxylin and eosin, Masson trichrome, alpha‐smooth muscle actin, IL‐33, CD8, and IL‐13 and analyzed by flow cytometry. Besides histomorphologic evaluation, the immunohistochemical stainings were analyzed for the respective cell numbers separately for tumor area, infiltrative margin, and distant liver stroma. These findings were correlated with clinical data and patient outcome. Further, gene expression of different HCC risk groups was compared using microarrays. In multivariable analysis, infiltration of HCCs by IL‐33 + cells ( P = 0.032) and CD8 + cells ( P = 0.014) independently was associated with prolonged patient survival. Flow cytometry demonstrated that cytotoxically active subpopulations of CD8 + cells, in particular CD8 + CD62L – KLRG1 + CD107a + effector‐memory cells, are the main producers of IL‐33 in these HCC patients. Using infiltration by IL‐33 + and CD8 + cells as two separate factors, an HCC immune score was designed and evaluated that stratified patient survival ( P = 0.0004). This HCC immune score identified high‐ and low‐risk patients who differ in gene expression profiles ( P < 0.001). Conclusion : Infiltration of HCCs by IL‐33 + and CD8 + cells is independently associated with prolonged patient survival. We suggest that this is due to an induction of highly effective, cytotoxically active CD8 + CD62L – KLRG1 + CD107a + effector‐memory cells producing IL‐33. Based on these two independent factors, we established an HCC immune score that provides risk stratification for HCC patients and can be used in the clinical setting. (H epatology 2015;61:1957‐1967)
科研通智能强力驱动
Strongly Powered by AbleSci AI